⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IBRX News
ImmunityBio, Inc. Common Stock
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline
globenewswire.com
IBRX
IBRX Lawsuit Alleges Company Allegedly Violated FDA Drug Rules - ImmunityBio Investors Face Losses Following Company Allegedly Violated FDA Drug Rules: SueWallSt
prnewswire.com
IBRX
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
accessnewswire.com
IBRX
Form 8-K
sec.gov
IBRX
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million
businesswire.com
IBRX
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of ImmunityBio, Inc. to Contact the Firm Today!
accessnewswire.com
IBRX
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
globenewswire.com
IBRX
IBRX DEADLINE NOTICE: ImmunityBio, Inc. Investors Encouraged to Contact Kirby McInerney LLP By May 26, 2026
accessnewswire.com
IBRX
Pomerantz LLP Issues Important Reminder to Investors in ImmunityBio, Inc. of Class Action – IBRX
accessnewswire.com
IBRX
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights
globenewswire.com
IBRX